Recruiting
Phase 2

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Sponsor:

Alliance for Clinical Trials in Oncology

Code:

NCT04803201

Conditions

Angioimmunoblastic T-cell Lymphoma

Enteropathy-Associated T-Cell Lymphoma

Follicular T-Cell Lymphoma

Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cyclophosphamide

Doxorubicin

Vincristine

Prednisone

Etoposide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information